['diabetes', 'diabetes mellitus, type 2']
['semaglutide', 'dulaglutide']

        Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed
        consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive)
        - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal
        tolerated dose documented in the patient medical record) for 90 days prior to screening
        Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant
        or is of child-bearing potential and not using an adequate contraceptive method (adequate
        contraceptive measures as required by local regulation or practice) - Any condition, which
        in the investigator's opinion might jeopardise subject's safety or compliance with the
        protocol - Treatment with any medication for the indication of diabetes or obesity other
        than stated in the inclusion criteria in a period of 90 days before screening. An exception
        is short-term insulin treatment for acute illness for a total of equal to or below 14 days
        - History of pancreatitis (acute or chronic) - Screening calcitonin equal to or above 50
        ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary
        Thyroid Carcinoma - Renal impairment defined as eGFR (electronic case report form) below 60
        mL/min/1.73 m^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) -
        Subjects presently classified as being in New York Heart Association Class IV - Planned
        coronary, carotid or peripheral artery revascularisation on the day of screening -
        Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of
        malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and
        in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more
        than 14 consecutive days or on a frequent basis) known to affect weight or glucose
        metabolism (e.g. orlistat, thyroid hormones, corticosteroids)
      